Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis

Trial Profile

A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Delusions; Hallucinations
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONY
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 04 Dec 2019 According to an Acadia Pharmaceuticals media release, ACADIA is planning to meet with the FDA in the first half of 2020 regarding a supplemental NDA submission
    • 04 Dec 2019 Results published in Acadia Pharmaceuticals media release.
    • 04 Dec 2019 According to an Acadia Pharmaceuticals media release, company presented positive top-line results HARMONY study at the 12th Clinical Trials on Alzheimers Disease (CTAD) Meeting, December 4 to 7, 2019 in San Diego, California
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top